Enteropathy-Associated T-Cell Lymphoma
Information
- Disease name
- Enteropathy-Associated T-Cell Lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03113500 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | May 25, 2017 | December 21, 2024 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT03049449 | Completed | Phase 1 | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | March 17, 2017 | January 26, 2022 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT05377827 | Recruiting | Phase 1 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | October 10, 2023 | April 30, 2026 |
| NCT04803201 | Recruiting | Phase 2 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | July 30, 2021 | January 1, 2026 |
| NCT05475925 | Recruiting | Phase 1/Phase 2 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | July 13, 2022 | December 2025 |
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT04480788 | Unknown status | Phase 1 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | November 24, 2020 | August 31, 2022 |
| NCT01719835 | Unknown status | Phase 2 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study | March 2012 | August 2022 |
| NCT04639843 | Withdrawn | Phase 1 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | November 3, 2022 | November 3, 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D058527